Dual MAPK / PI3K pathway inhibition with trametinib and...

  • Main
  • 2017 / 09
  • Dual MAPK / PI3K pathway inhibition with trametinib and...

Dual MAPK / PI3K pathway inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS mutant and wild type melanoma

Algazi, Alain P., Esteve-Puig, Rosaura, Nosrati, Adi, Hinds, Brian, Hobbs-Muthukumar, Adele, Nandoskar, Prachi, Ortiz-Urda, Susana, Chapman, Paul B., Daud, Adil
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Pigment Cell & Melanoma Research
DOI:
10.1111/pcmr.12644
Date:
September, 2017
File:
PDF, 516 KB
english, 2017
Conversion to is in progress
Conversion to is failed